Liposomal doxorubicin (TLC D99, myocet) in combination with cyclophosphamide (C), vincristine (O) and prednisone (P) for aggressive non-Hodgkin's lymphomas (NHL).

被引：0
|
作者：
Levine, A
Tulpule, A
Espina, B
Buchanan, L
Africano, M
Welles, L
机构：
[1] Univ So Calif, Norris Canc Hosp, Los Angeles, CA USA
[2] Med Res, Princeton, NJ USA
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
478P
引用
收藏
页码：105 / 106
页数：2
相关论文
共 50 条
  • [21] A phase I study of pixantrone (BBR 2778) in combination with cyclophosphamide, vincristine and prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma.
    Borchmann, P
    Schnell, R
    Morschhauser, F
    Hess, G
    Harousseau, JL
    Herbrecht, R
    Derigs, HG
    Dreyfus, F
    Schouten, HC
    Engert, A
    Camboni, G
    BLOOD, 2003, 102 (11) : 642A - 642A
  • [22] Long term remission of Sjogren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)
    Voulgarelis, M.
    Giannouli, S.
    Tzioufas, A. G.
    Moutsopoulos, H. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (08) : 1033 - 1037
  • [23] R-COMP 21 (Prednisone, Cyclophosphamide, Vincristine, Myocet™ and rituximab) for frail and elderly patients with aggressive B-Cell non-Hodgkin lymphoma:: A pilot study
    Isidori, Alessandro
    Ferrara, Felicetto
    Alesiani, Francesco
    Ronconi, Sonia
    Catarini, Massimo
    D'Adamo, Francesca
    Guiducci, Barbara
    Bernardi, Daniele
    Visani, Giuseppe
    BLOOD, 2007, 110 (11) : 180B - 180B
  • [24] Preliminary results of a phase II trial of pegylated liposomal doxorubicin (Doxil), rituxan, cyclophosphamide, vincristine, and prednisone (DR-COP) in aggressive B-cell non-Hodgkin's lymphoma.
    Tulpule, A
    Khan, AU
    Mohrbacher, A
    Weitz, IC
    Espina, BM
    Boswell, WD
    Nathwani, BN
    Levine, AM
    BLOOD, 2003, 102 (11) : 286B - 286B
  • [25] A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressive non-Hodgkin lymphoma
    Mitchell, Paul L. R.
    Marlton, Paula
    Grigg, Andrew
    Seymour, John F.
    Hertzberg, Mark
    Enno, Arno
    Herrmann, Richard
    Bond, Rodney
    Arthur, Chris
    LEUKEMIA & LYMPHOMA, 2008, 49 (05) : 924 - 931
  • [26] Phase II study of cyclophosphamide, prednisone, and etoposide (CEOP-E) lymphoma epirubicin, vincristine, for aggressive non-Hodgkin's
    Kim, JG
    Sohn, SK
    Kim, DH
    Baek, JH
    Park, TI
    Lee, KB
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2004, 19 (06) : 820 - 825
  • [27] Cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) plus rituximab is effective and well tolerated in poor performance status elderly patients with non-Hodgkin's lymphoma
    Visani, G
    Guiducci, B
    D'Adamo, F
    Mele, A
    Nicolini, G
    Leopardi, G
    Sparaventi, G
    Barulli, S
    Malerba, L
    Isidori, A
    Malagola, M
    Piccaluga, PP
    LEUKEMIA & LYMPHOMA, 2005, 46 (03) : 477 - 479
  • [28] Salvage chemotherapy using a combination of fludarabine and cyclophosphamide for refractory or relapsing indolent and aggressive non-Hodgkin's lymphomas
    Lossos, IS
    Paltiel, O
    Polliack, A
    LEUKEMIA & LYMPHOMA, 1999, 33 (1-2) : 155 - 160
  • [29] Preliminary phase II study results of BBR2778 in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma.
    Herbrecht, R
    Borchmann, P
    Wilhelm, M
    Morschhauser, F
    Hess, G
    Kutz, K
    Comis, S
    Laffranchi, BL
    Engert, A
    BLOOD, 2004, 104 (11) : 682A - 683A
  • [30] Treatment of aggressive non-Hodgkin's lymphoma with dose-intensified epirubicin in combination of cyclophosphamide, vincristine, and prednisone (CEOP-100) - A phase II study
    Basaran, M
    Bavbek, ES
    Sakar, B
    Eralp, Y
    Alici, S
    Tas, F
    Yaman, F
    Dogan, O
    Camlica, H
    Onat, H
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2001, 24 (06): : 570 - 575
12345